Overview
Ocular cystinosis, also called non-nephropathic cystinosis or benign cystinosis, is a rare inherited metabolic disorder that affects the eyes. It is the mildest form of cystinosis, a group of conditions caused by the buildup of an amino acid called cystine inside cells. In ocular cystinosis, cystine crystals accumulate mainly in the cornea (the clear front part of the eye), while the kidneys and other organs are typically spared. This sets it apart from the more severe infantile (nephropathic) form of cystinosis, which causes serious kidney damage early in life. People with ocular cystinosis usually develop symptoms in late childhood, adolescence, or adulthood. The hallmark sign is the presence of cystine crystals in the cornea, which can cause light sensitivity (photophobia), eye irritation, tearing, and sometimes a feeling of grittiness in the eyes. Vision may be mildly affected over time, but many individuals maintain good overall eyesight. Because the disease is limited to the eyes, people with this form generally have a normal lifespan and do not develop the kidney failure or growth problems seen in more severe types of cystinosis. Treatment focuses on managing eye symptoms. Cysteamine eye drops (brand name Cystaran or Cystadrops) are the main therapy and work by dissolving the cystine crystals in the cornea. These drops need to be used regularly throughout the day. Lubricating eye drops and sunglasses can also help with comfort. There is currently no cure, but with consistent treatment, symptoms can be well controlled.
Also known as:
Key symptoms:
Sensitivity to bright light (photophobia)Eye irritation or discomfortTearing or watery eyesGritty feeling in the eyesVisible crystals in the cornea on eye examMild blurring of visionEye rednessDifficulty with glare
Clinical phenotype terms (4)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
4 eventsNovartis Pharmaceuticals — PHASE1
PROCYSBI: FDA approved
PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Cystagon: FDA approved
Treatment of nephropathic cystinosis in adults and children.
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availablePROCYSBI
PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Rare Disease Specialist
Treatment Centers
8 centersHôpital Femme Mère Enfant
📍 Bron
👤 Justine BACCHETTA, MD PhD
Stanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🏥 NORDBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
Financial Resources
1 resourcesTravel Grants
No travel grants are currently matched to Ocular cystinosis.
Community
No community posts yet. Be the first to share your experience with Ocular cystinosis.
Start the conversation →Latest news about Ocular cystinosis
Disease timeline:
New trial: DFT383 in Pediatric Participants With Nephropathic Cystinosis
Phase PHASE1 trial recruiting. DFT383
New trial: CYSTEA-BONE Clinical Study
Phase NA trial recruiting. Blood sampling
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How severe are the cystine crystal deposits in my (or my child's) corneas right now?,How often do the cysteamine eye drops need to be used, and are there tips to make the schedule easier?,Do we need to test for kidney or other organ involvement to rule out more severe forms of cystinosis?,What genetic testing should family members consider, especially if we plan to have more children?,Are there any newer or longer-acting eye drop formulations available or in clinical trials?,How often should follow-up eye exams be scheduled?,What should I watch for that would indicate the condition is getting worse?
Common questions about Ocular cystinosis
What is Ocular cystinosis?
Ocular cystinosis, also called non-nephropathic cystinosis or benign cystinosis, is a rare inherited metabolic disorder that affects the eyes. It is the mildest form of cystinosis, a group of conditions caused by the buildup of an amino acid called cystine inside cells. In ocular cystinosis, cystine crystals accumulate mainly in the cornea (the clear front part of the eye), while the kidneys and other organs are typically spared. This sets it apart from the more severe infantile (nephropathic) form of cystinosis, which causes serious kidney damage early in life. People with ocular cystinosis
How is Ocular cystinosis inherited?
Ocular cystinosis follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Are there clinical trials for Ocular cystinosis?
Yes — 2 recruiting clinical trials are currently listed for Ocular cystinosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Ocular cystinosis?
17 specialists and care centers treating Ocular cystinosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Ocular cystinosis?
2 patient support programs are currently tracked on UniteRare for Ocular cystinosis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.